Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flecainide

R H Falk1, R I Fogel

  • 1Section of Cardiology, Boston University School of Medicine, Massachusetts.

Journal of Cardiovascular Electrophysiology
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Flecainide, a Class IC antiarrhythmic, effectively treats supraventricular arrhythmias due to its low side effect profile. However, concerns about proarrhythmia limit its use in ventricular arrhythmias, especially post-myocardial infarction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcium-Proton Exchange During Algal Calcification.

The Biological bulletin·2018
Same author

Amyloid diseases of the heart: assessment, diagnosis, and referral.

Heart (British Cardiac Society)·2010
Same author

High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.

Bone marrow transplantation·2003
Same author

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Bone marrow transplantation·2001
Same author

Amyloidosis.

Postgraduate medical journal·2001
Same author

Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts.

Circulation·2001
Same journal

Pulsed Field Ablation Is Associated With Fewer Post-Procedural Pericardial Inflammatory Symptoms Compared With Radiofrequency Ablation.

Journal of cardiovascular electrophysiology·2026
Same journal

Single-Cell Transcriptomics and Mendelian Randomization Analysis Reveal Key Genes in Atrial Fibrillation.

Journal of cardiovascular electrophysiology·2026
Same journal

Relationship Between Nonuniform Isochrone-Area in Late Activation Mapping and Arrhythmogenic Substrates Related to Atrial Fibrillation.

Journal of cardiovascular electrophysiology·2026
Same journal

Clinical Utility of Tissue Proximity Indication With a Variable-Loop Circular Catheter for Pulmonary Vein Isolation.

Journal of cardiovascular electrophysiology·2026
Same journal

Impact of Carina Width on Re-Ablation Rate of Atrial Fibrillation After Primary Cryoballoon-Ablation.

Journal of cardiovascular electrophysiology·2026
Same journal

Mediastinal Air Entrapment During Extravascular ICD Implantation: A Preventable Cause of Elevated Shock Impedance.

Journal of cardiovascular electrophysiology·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Flecainide is a Class IC antiarrhythmic drug.
  • It primarily slows cardiac conduction.
  • Class IC agents are known for potential proarrhythmic effects.

Purpose of the Study:

  • To review the electrophysiologic effects of flecainide.
  • To evaluate its efficacy and safety in various arrhythmias.
  • To understand its role in clinical practice.

Main Methods:

  • Review of flecainide's electrophysiologic properties.
  • Analysis of clinical trial data, including the CAST trial.
  • Assessment of efficacy in supraventricular and ventricular arrhythmias.

Main Results:

Related Experiment Videos

  • Flecainide effectively suppresses premature ventricular contractions and nonsustained ventricular arrhythmias.
  • Its efficacy is modest when electrophysiologic testing is the endpoint.
  • The CAST trial indicated a risk of proarrhythmia, particularly in post-myocardial infarction patients.
  • Flecainide has a low noncardiac side effect profile.

    • Conclusions:

    • Flecainide is effective for supraventricular arrhythmias due to its favorable side effect profile.
    • Concerns regarding proarrhythmia have reduced its use for ventricular arrhythmias, especially in high-risk patients.
    • Careful patient selection is crucial for flecainide therapy.